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distance outside the practice—this would provide a
useful public service.
Conclusions
Snellen acuity is a poor indicator of an individual’s
chance of passing a number plate test, and it cannot be
assumed that a driver with a visual acuity of 6/9 will
meet the standard for driving. All drivers with 6/9
vision or less must be encouraged to self assess.
Conversely, it should not be assumed that a driver with
a visual acuity of 6/12 is below the standard for driving,
particularly as loss of the right to drive has such far
reaching social implications.7 8 Advice that vision
required for driving lies somewhere between 6/9 and
6/12 acuity could cause confusion if these points are
not stressed.
AB’s current address is Queens Medical Centre, Nottingham
NG7 2UH.
Contributors: ZC contributed to the design of the study and
questionnaire, distribution of the questionnaire, patient testing,
analysis of the results, and writing the paper; she will act as guar›
antor. AB contributed to the distribution of the questionnaire,
patient testing, and writing the paper. IP contributed to the
analysis of the results, patient testing, and writing the paper.
Funding: None.
Competing interests: None declared.
1 Driver and Vehicle Licensing Authority. At a glance guide to the current
medical standards of fitness to drive. Swansea: Drivers Medical Unit, DVLA,
1998:25›6.
2 Marsden AM, Packer AL. The visibility of vehicle number plates. Trans
Illuminating Eng Soc (London) 1966;31:2.
3 Drasdo N, Haggerty CM. A comparison of the British number plate and
Snellen vision tests for car drivers. Ophthalmol Physiol Opt 1981;1:39›54.
4 Taylor SP. Accuracy of recall of the legal number plate testing distance by
UK drivers. Ophthalmol Physiol Opt 1997;17:473›7.
5 Department of Transport. Consumer trends survey Aug, 1998.
6 McCaghrey GE. AOP vision screening 1985/86. Optom Today
1987;27:178›81.
7 Shipp MD, Penchanski R. Vision testing and the elderly driver: is there a
problem meriting policy change? J Am Optom Assoc 1995;66:343›51.
8 Charman WN. Visual standards for driving. Ophthalmol Physiol Opt
1985;5:211›20.
(Accepted 24 July 2000)
Unjustified exclusion of elderly people from studies
submitted to research ethics committee for approval:
descriptive study
Antony Bayer, Win Tadd
Ageism in clinical practice1 and published research2 is
well recognised. We were interested in whether
research protocols submitted to the local research
ethics committee contained unjustified upper age
limits and how the committee dealt with this.
Methods and results
We reviewed all studies submitted to Bro Taf local
research ethics committee in the first seven months of
1999 to determine whether any upper age limits were
justified and whether the committee had commented
on such age restrictions. We then made a judgment on
the appropriateness of the upper age limit.
Of 225 studies whose protocols were reviewed, 65
were on topics or conditions that automatically
excluded elderly people. Five studies specifically
concerned elderly people and had a lower age limit but
no upper limit. Of the remaining 155, 90 (58%) had an
upper age limit, which ranged from 45 years (in a
smoking cessation intervention) to 100 years (in a
study of an open access mental health service), with a
median of 70 years (interquartile range 65 to 75 years).
In five studies an upper age limit was reasonable (par›
ticipants were required to have no important disease,
or prolonged follow up was planned).
In 85 studies the age restriction was inappropriate
and unnecessary, but ethical review had failed to high›
light this issue. Justification was offered by researchers
in only one study. Age limits often conflicted with the
aims of the study—for example, in a study of “subjects
randomly selected to reflect each life stage,” another “of
consecutive patients attending for bone scan,” and
another that claimed “no special groups to be
excluded.” In some studies exclusion of older patients
was likely to result in an atypical clinical population—
for example, an investigation of “exclusion of
vulnerable people from services,” studies of type II
diabetes, glaucoma, or non›steroidal anti›inflammatory
drugs that were restricted to people aged under 65,
and a study comparing incontinence aids that was lim›
ited to those aged under 70.
What is already known on this topic
It is estimated that a Snellen acuity of 6/9 − 2
produces the same failure rate as the number
plate test at 20.5 m, leading to guidelines that a
visual acuity between 6/9 and 6/12 is required for
driving
What this study adds
A proportion of patients with binocular 6/9 vision
failed to read a number plate at 20.5 m, and a
major proportion with binocular 6/12 vision
could read it
Snellen visual acuity is a poor indicator of an
individual’s chance of meeting the legal standard
for driving, and all people with a visual acuity of
6/9 or less should be encouraged to self assess
their vision
Patients receive a spectrum of advice from
healthcare professionals about driving on the basis
of a visual acuity of 6/9 or 6/12
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A total of 46 studies were approved by a multi›
centre research ethics committee; of these 20 had an
upper age limit that seemed unjustifiable.
Comment
Of the 155 studies that were of relevance to elderly
people, over half had an upper age limit that was
unjustified, and neither the local ethics committee nor
the multicentre research ethics committee had
requested justification for the age restrictions.
Negative stereotyping of elderly people was
reflected in comments in the studies that participants
need to be “fully competent,” “reliable,” or “without
cognitive impairment.” One argument for an upper
age limit is that it minimises the rate of dropout. How›
ever, we know of no evidence that elderly people are
less compliant with the demands of research protocols,
and their fewer family and employment commitments
may make participation easier.
Furthermore, exclusion of elderly participants can
affect the generalisability of a study’s findings. If
researchers can be certain that elderly people will not
respond differently from other age groups, their
specific inclusion may not be an issue; if this is not the
case, however, their inclusion is essential.3 Abolishing
ageist practices and attitudes in research, as well
as in clinical practice, is important if elderly people
are to gain maximum benefit from advances in
health care.4
Ethics committees are in a strong position to
influence research practice and to reduce unethical
age discrimination. We encourage them to request
justification whenever protocols include inappropri›
ate age restrictions—and if this is not forthcoming,
approval might be conditional on age limits being
removed. This policy would promote more positive
attitudes towards elderly people among researchers
as well as safer, more effective treatments and services.
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A memorable patient
Never has a three hour flight seemed so long
“The pilot would like to know if you would have him land the
airplane in Bermuda,” the British West Indies Airline flight
attendant asked, quietly and professionally. “No,” I replied, “there
is no cardiac surgeon there.”
Reisha, my 4 month old patient, had picked an unfortunate day
to try to die. We knew that she had heart disease soon after she
was born. She first developed cyanotic spells, the hallmark of
tetralogy of Fallot, at 2 months. In Antigua and Barbuda it takes
time to arrange for overseas evaluation and care, but with the
help of the Rotary club and its Gift of Life programme we had
been able to arrange for transport to Schneider Children’s
Hospital in New York.
In the three days before departure the cyanotic spells became
more frequent and more pronounced. She had been treated with
oxygen, morphine, and propranolol. An air ambulance would have
been more appropriate for transfer, but the cost is overwhelming in
a developing country. So we claimed that she was fit to fly on a
commercial flight. A nurse from the special care unit at Holberton
Hospital accompanied Reisha, her mother, and me.
Reisha dropped her oxygen saturation to 40% in the
ambulance on the way to the airport, so we drove on to the
tarmac and boarded while providing her with bag and mask
ventilation with oxygen. She did not seem to like the rarefied
atmosphere over the Atlantic and proceeded to drop her oxygen
level to 30% on a regular basis. She was given morphine and
needed ventilation for her subsequent apnoea and to try to lower
her pulmonary resistance to improve lung blood flow. Her oxygen
rose temporarily to 95% and then it would fall again.
We had adrenaline, which we began as a bolus to raise systemic
resistance and theoretically increase the blood flow to the lungs. It
worked when the oxygen level fell to 40%, but after each
treatment Reisha’s pulse and oxygen level were not detectable for
about five minutes. My heart would stop and restart when her
oxygen level rose again to 95%. We began chest compressions
when we weren’t sure. Between adrenaline doses the intravenous
line dislodged. I didn’t need to tell the nurse that failure to resite
the line would result in Reisha’s death. The nurse replaced the
line at the first try, in a darkened airplane, at 30 000 feet.
It was then that the flight attendant made her offer. About that
time the adrenaline bolus technique was becoming less effective,
so we began an adrenaline infusion and occasional sodium
bicarbonate. Mainlining adrenaline is a desperate measure, even
at sea level.
I don’t think that a three hour flight ever lasted so long. But,
together with bag and mask oxygen, adrenaline, bicarbonate, and
morphine, we made it to New York. We were processed in our
seats and the transport team worked for 45 minutes before
Reisha was stable enough for the ambulance drive. On arrival at
the intensive care unit her pa02 was 25 torr and her pH 7.40. I
worried about her brain.
She underwent emergency placement of a Blaylock›Taussig
shunt and complete repair of her tetralogy of Fallot defect one
year later. She is now 4 and due to start school this fall with her
twin sister and is now developing normally.
Thomas C Martin consultant paediatrician and cardiologist, Antigua
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